The Biotechnology and Medical Devices industries saw venture
capitalists invest a total of $1.5 billion in the first quarter of
2012. While Medical Device venture funding accelerated, it could
not offset the slowdown in Biotechnology and the first quarter of
2012 decreased 22% from the fourth quarter of 2011. Deal volume was
also down from the previous quarter, dropping 11% to 171 deals.
This quarterly summary includes data on where venture capital
investments and funding were made, the nature of transactions that
took place as well as the geographic distribution of funding for
the biotechnology and medical device sectors during the first
Mobile technology has long been viewed as an innovation with
much potential to transform the healthcare industry and address
long-standing issues. Yet there is little understanding of how to
harness its power or develop business models that work.
Emerging mHealth: Paths for Growth, an Economist Intelligence
Unit report commissioned by PwC examines the current state and
potential of mHealth in developed and emerging markets, the ongoing
barriers to its adoption and the implications for companies in the
Key insights include:
Consumer behaviour — their expectations and
preferences, and how mHealth can drive change
Ingredients for successful mHealth business models
The impact of mobile technology, and why it will become one of
the most dominant models of delivery in healthcare
The House Ways and Means Committee yesterday voted 23 to 11 to
approve the "Protect Medical Innovation Act" (H.R. 436),
a bill to repeal a medical device excise tax scheduled to be
effective in 2013 under the 2010 health care law. The Ways and
Means Committee also approved a bill providing for a $500 taxable
cash-out exception from flexible spending account
"use-it-or-lose-it" rules (H.R. 1004); a bill repealing a
restriction on use of flexible spending accounts to purchase
over-the-counter drugs (H.R. 5842); and a bill modifying health
savings account rules (H.R. 5858). The full House is expected to
vote on the four health care-related measures as early as next
In the face of business model challenges, declining R&D
budgets, and expirations of blockbuster patents, the
pharmaceuticals and life sciences industry is among several that
may benefit from a proposed US "patent box" tax regime. A
US patent box — deriving its name from a box on the
corporate tax form — would reward companies for
commercializing innovative products by taxing the profits on their
sale at a reduced rate. Such a regime in the United States could
substantially reduce what now ranks as the highest tax rate among
the Organization for Economic Cooperation and Development (OECD)
countries for intellectual property (IP) income.
Supporters of a US patent box regime suggest, among other
things, that it would further competitiveness of US companies and
encourage the development and retention of IP within US borders. As
some countries have done, the scope of the patent box regime could
be expanded beyond patents to encourage a broader array of
innovation-based intellectual property.
Effective September 1, 2016, the Disposition of Surplus Real Property Regulation to the Ontario Education Act was amended with the intention to reduce barriers to the formation of health and community hubs in Ontario.
Health Canada is proposing to change the way that it regulates non-prescription drugs, natural health products and cosmetics in Canada, which will now be referred to collectively as "self-care products."
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).